Overview

Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)

Status:
Terminated
Trial end date:
2016-11-08
Target enrollment:
Participant gender:
Summary
Efficacy and safety of octaplasLG® administration vs. crystalloids (standard) in patients with septic shock - a randomized, controlled, open-label investigator-initiated pilot trial.
Phase:
Phase 4
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborator:
Octapharma